Hormone Resistant Prostate Cancer Completed Phase 1 / 2 Trials for Abiraterone (DB05812)

Also known as: Hormone-Resistant Prostate Cancer

IndicationStatusPhase
DBCOND0038482 (Hormone Resistant Prostate Cancer)Completed1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01848067Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate CancerTreatment